Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 research study open to eligible people
Anti-NMDA receptor encephalitis happens when the immune system attacks the brain by mistake. UCSF is running trials to see if satralizumab can treat this illness. They are also studying the safety and behavior of the drug in the body.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Last updated: